Polygenic Score (PGS) ID: PGS003488

Predicted Trait
Reported Trait General atopic disease (IL-12 related variants)
Mapped Trait(s) allergic disease (MONDO_0005271)
Released in PGS Catalog: April 12, 2023
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name PRS_IL12
Development Method
Name Genome-wide significant SNPs
Parameters r2<0.2, SNPS implicated in the IL-12 pathway
Variants
Original Genome Build hg19
Number of Variants 10
Effect Weight Type beta
PGS Source
PGS Catalog Publication (PGP) ID PGP000451
Citation (link to publication) Al-Janabi A et al. J Invest Dermatol (2023)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 100%
1,225,820 individuals (100%)
PGS Evaluation
European: 100%
1 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
doi.org/10.1101/2022.10.05.22279072
[
  • 60,653 cases
  • , 804,329 controls
]
 European NR
GWAS Catalog: GCST005038
Europe PMC: 29083406
 360,838 individuals European NR

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM017416 PSS010186|
European Ancestry|
3,212 individuals
 PGP000451 |
Al-Janabi A et al. J Invest Dermatol (2023)
 Reported Trait: Paradoxical eczema in biologic-treated psoriasis OR: 4.89 [1.03, 23.29] — — PCs 1-2 —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS010186 Plaque psoriasis patients with at least one exposure to biologic therapy. Cases developed one or more paradoxical eczema adverse events during treatment with one of the following biologics: TNF-alpha inhibitors (adalimumab; etanercept; certolizumab; infliximab), IL-17 inhibitors (brodalumab; secukinumab; ixekizumab), IL-12/23 inhibitors (ustekinumab) and IL-23p19 inhibitors (guselkumab; risankizumab; tildrakizumab). Controls has no recorded eczema events during biologic therapy. Participants may have been exposed to more than one biologic. —
[
  • 88 cases
  • , 3,124 controls
]
 — European — BSTOP —